A Randomised Comparative Trial of Adriamycin + Taxotere vs. Adriamycin + Cyclophosphamide as Primary Medical Therapy for Patients With Potentially Operable Breast Cancer Greater Than or Equal to 3 cm Diameter, Locally Advanced, or Inflammatory Disease

Trial Profile

A Randomised Comparative Trial of Adriamycin + Taxotere vs. Adriamycin + Cyclophosphamide as Primary Medical Therapy for Patients With Potentially Operable Breast Cancer Greater Than or Equal to 3 cm Diameter, Locally Advanced, or Inflammatory Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2010

At a glance

  • Drugs Cyclophosphamide; Docetaxel; Doxorubicin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms Anglo-Celtic-IIA
  • Most Recent Events

    • 01 Aug 2010 Long-term results published in Breast Cancer Research and Treatment.
    • 13 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 26 Jul 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top